Targeted therapy: ARIEL3 — broad benefit of PARP inhibitors in ovarian cancer

Targeted therapy: ARIEL3 — broad benefit of PARP inhibitors in ovarian cancerNature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.161

Source: Nature Clinical Practice Oncology - October 10, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research